About the Authors
- Scott G Filler
-
*To whom correspondence should be addressed. E-mail: sfiller@ucla.edu
- Donald C Sheppard
Competing Interests
Scott G. Filler has equity in Novadigm Therapeutics, a company that is developing a vaccine against C. albicans.
Author Contributions
SGF and DCS wrote the paper.